Lilly Collaborates With T1D Exchange To Advance Diabetes Care Initiatives

Eli Lilly announced that it has entered into research collaboration with T1D Exchange to identify new ways to enhance diabetes care and advance outcomes.

The multi-year collaboration will see the combination of Lilly’s expertise in Type 1 diabetes with T1D Exchange’s patient-centric model clinic registry to launch several projects over an initial five year period.

Dara Schuster, Medical Fellow at Lilly Diabetes, said, “Lilly's commitment to supporting people with type 1 diabetes dates back to 1923 when we introduced the first commercially available insulin. Having access to the resources of T1D Exchange to bolster our understanding of the needs of people with type 1 diabetes, their caregivers and health care providers will help us continue our mission of addressing the global diabetes burden through the development of innovative medicines and programs.”

Kick-starting the collaboration will be the launch of the first project assessing user experience associated with insulin pumps and multiple daily injections. Data from T1D Exchange’s will be analyzed to guide development of a survey of health care providers from the company’s clinical registry of over 26,000 people and members of its Glu community. Glu is a patient and caregiver online community for T1D. The survey will be followed by a study of clinic registry participants to further inform how insulin pumps are used and how multiple daily injections occur in real practice.

Dr. Roy Beck, Director of T1D Exchange Clinic Coordinating Center and Executive Director of JAEB Center for Health Research, said, “The T1D Exchange Clinic Registry was established to provide real-world data on a large number of children and adults with type 1 diabetes to serve as a resource for both academic and company researchers. This collaboration with Lilly is a great example of how the registry data can be used to address key issues that are important to individuals with type 1 diabetes.”

Recommendations that will emerge from the research will be shared with the public once analysis is complete for the benefit of both Type 1 diabetes and researcher communities, the companies stated.